Form 4 for BIIB Biogen
Accepted 2023-07-05 00:00:00 ET · period of report 2023-06-30 · accession 0001127602-23-020238 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-07-05 | 2023-06-30 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | +504 | 6,388 | +9% | $0 |
| D | 2023-07-05 | 2023-06-30 | BIIB | Izzar Rachid | Head of Gbl Product Strat | F - Tax | $284.85 | -244 | 6,144 | -4% | -$69.5K |
| D | 2023-07-05 | 2023-06-30 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | -504 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-30 | M | A | 504 | $0.00 | 6,388 | D | — | — | |
| 2 | Common | Common Stock | 2023-06-30 | F | D | 244 | $284.85 | 6,144 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2023-06-30 | M | D | 504 | $0.00 | 0 | D | $0.00 · — to 2024-07-01 | 504 Common Stock | (F1) This award was granted to the reporting person on July 1, 2020, and vested in three equal installments on each anniversary of the grant date. |